Geraldine J Ooi1, Paul R Burton2,3, Lisa Doyle2, John M Wentworth2,4, Prithi S Bhathal5, Ken Sikaris6, Michael A Cowley7, Stuart K Roberts8, William Kemp8, Paul E O'Brien2, Wendy A Brown2,3. 1. Centre for Obesity Research and Education, Monash University, 99 Commercial Road, Melbourne, Australia. geraldine.ooi@monash.edu. 2. Centre for Obesity Research and Education, Monash University, 99 Commercial Road, Melbourne, Australia. 3. Monash University Department of Surgery, Alfred Hospital, Melbourne, Australia. 4. Walter and Eliza Hall Institute, Melbourne University, Melbourne, Australia. 5. Department of Pathology, University of Melbourne, Melbourne, VIC, Australia. 6. Melbourne Pathology, East Melbourne, Australia. 7. MODI, Monash University, Melbourne, Australia. 8. Department of Gastroenterology, Alfred Hospital, Melbourne, Australia.
Abstract
BACKGROUND: Obesity and its related comorbidities are significant risk factors for nonalcoholic fatty liver disease (NAFLD). Liver fibrosis is the major determinant of long-term outcomes in NAFLD. A non-invasive tool that accurately identifies obese patients at elevated risk of liver fibrosis would be of significant value. Fibrosis risk scores in patients with NAFLD have been proposed but have not been validated in obese populations. We aimed to validate established simple fibrosis scores in bariatric surgical patients. METHODS: We conducted a prospective study of 107 consecutive high-risk obese patients undergoing primary bariatric surgery. Proposed fibrosis scores (NAFLD fibrosis score; body mass index (BMI), aspartate aminotransferase (AST)/alanine aminotransferase ratio (ALT), and diabetes (BARD); Fibrosis-4 (FIB-4); Forn; and AST to platelet ratio index) were calculated and compared hepatic fibrosis determined by histology of intraoperative liver biopsies. Accuracy was determined, and fibrosis score thresholds were optimized. These modified thresholds were then validated in an independent bariatric surgical population. RESULTS: Liver biopsies were available in 101 patients. Sixty-eight patients had some degree of fibrosis, with 23 patients (23 %) having significant fibrosis (F2-4). The Forn score best predicted significant fibrosis (area under the receiver operator characteristic curve (AUROC) 0.724, p = 0.001). With standard thresholds, the sensitivity for the Forn score for identification of significant fibrosis (F2-4) was 0 %. Using modified thresholds of 3.5, the sensitivity and negative predictive value increased to 85.7 and 94.7 %. This threshold was applied to an independent validation cohort with good accuracy. CONCLUSIONS: Fibrosis risk scores using simple markers have moderate success at delineating obese patients with significant NAFLD-related fibrosis. Thresholds, however, need to be lowered to maximize diagnostic accuracy in this cohort.
BACKGROUND: Obesity and its related comorbidities are significant risk factors for nonalcoholic fatty liver disease (NAFLD). Liver fibrosis is the major determinant of long-term outcomes in NAFLD. A non-invasive tool that accurately identifies obesepatients at elevated risk of liver fibrosis would be of significant value. Fibrosis risk scores in patients with NAFLD have been proposed but have not been validated in obese populations. We aimed to validate established simple fibrosis scores in bariatric surgical patients. METHODS: We conducted a prospective study of 107 consecutive high-risk obesepatients undergoing primary bariatric surgery. Proposed fibrosis scores (NAFLD fibrosis score; body mass index (BMI), aspartate aminotransferase (AST)/alanine aminotransferase ratio (ALT), and diabetes (BARD); Fibrosis-4 (FIB-4); Forn; and AST to platelet ratio index) were calculated and compared hepatic fibrosis determined by histology of intraoperative liver biopsies. Accuracy was determined, and fibrosis score thresholds were optimized. These modified thresholds were then validated in an independent bariatric surgical population. RESULTS: Liver biopsies were available in 101 patients. Sixty-eight patients had some degree of fibrosis, with 23 patients (23 %) having significant fibrosis (F2-4). The Forn score best predicted significant fibrosis (area under the receiver operator characteristic curve (AUROC) 0.724, p = 0.001). With standard thresholds, the sensitivity for the Forn score for identification of significant fibrosis (F2-4) was 0 %. Using modified thresholds of 3.5, the sensitivity and negative predictive value increased to 85.7 and 94.7 %. This threshold was applied to an independent validation cohort with good accuracy. CONCLUSIONS:Fibrosis risk scores using simple markers have moderate success at delineating obesepatients with significant NAFLD-related fibrosis. Thresholds, however, need to be lowered to maximize diagnostic accuracy in this cohort.
Authors: V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard Journal: Gastroenterology Date: 2000-06 Impact factor: 22.682
Authors: David E Kleiner; Paul D Berk; Jesse Y Hsu; Anita P Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L Machado; Bruce M Wolfe; Steven H Belle Journal: Semin Liver Dis Date: 2014-04-29 Impact factor: 6.115
Authors: Sherene Shalhub; Anna Parsee; Scott F Gallagher; Krista L Haines; Chris Willkomm; Stephen G Brantley; Haim Pinkas; Lisa Saff-Koche; Michel M Murr Journal: Obes Surg Date: 2004-01 Impact factor: 4.129
Authors: Karel Dvorak; Jan Stritesky; Jaromir Petrtyl; Libor Vitek; Renata Sroubkova; Martin Lenicek; Vaclav Smid; Martin Haluzik; Radan Bruha Journal: PLoS One Date: 2014-10-28 Impact factor: 3.240
Authors: Geraldine J Ooi; Paul R Burton; Arul Earnest; Cheryl Laurie; William W Kemp; Peter D Nottle; Catriona A McLean; Stuart K Roberts; Wendy A Brown Journal: Obes Surg Date: 2018-02 Impact factor: 4.129
Authors: Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown Journal: Obes Surg Date: 2017-06 Impact factor: 4.129
Authors: Patrick H Alizai; Isabella Lurje; Andreas Kroh; Sophia Schmitz; Tom Luedde; Julia Andruszkow; Ulf P Neumann; Florian Ulmer Journal: Gastroenterol Res Pract Date: 2019-02-03 Impact factor: 2.260
Authors: Jacqueline Bayliss; Geraldine J Ooi; William De Nardo; Yazmin Johari Halim Shah; Magdalene K Montgomery; Catriona McLean; William Kemp; Stuart K Roberts; Wendy A Brown; Paul R Burton; Matthew J Watt Journal: Front Endocrinol (Lausanne) Date: 2021-03-04 Impact factor: 5.555
Authors: Ahmad Hassan Ali; Alhareth Al Juboori; Gregory F Petroski; Alberto A Diaz-Arias; Majid M Syed-Abdul; Andrew A Wheeler; Rama R Ganga; James B Pitt; Nicole M Spencer; Ghassan M Hammoud; R Scott Rector; Elizabeth J Parks; Jamal A Ibdah Journal: J Clin Med Date: 2022-02-23 Impact factor: 4.964
Authors: Andreas Drolz; Stefan Wolter; Malte H Wehmeyer; Felix Piecha; Thomas Horvatits; Julian Schulze Zur Wiesch; Ansgar W Lohse; Oliver Mann; Johannes Kluwe Journal: Int J Obes (Lond) Date: 2021-06-24 Impact factor: 5.095